Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2021 Earnings Conference Call March 14, 2022 8:30 AM ET
Company Participants
Juli Miller - Investor Relations
Adrian Rawcliffe - Chief Executive Officer
Dennis Williams - Senior Vice President, Late Stage Development
Elliot Norry - Chief Medical Officer
John Lunger - Chief Patient Supply Officer
Helen Tayton-Martin - Chief Business Officer
Karen Miller - Senior Vice President, Pipeline Research
Gavin Wood - Chief Financial Officer
Conference Call Participants
Marc Frahm - Cowen
Nick Abbott - Wells Fargo
Disclaimer*: This transcript is designed to be used alongside the freely available audio recording on this page. Timestamps within the transcript are designed to help you navigate the audio should the corresponding text be unclear. The machine-assisted output provided is partly edited and is designed as a guide.
Operator
00:04 Good day. Thank you for standing by. Welcome to the Full-Year and Fourth Quarter 2021 Adaptimmune Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker’s remarks, there will be a question-and-answer session. [Operator Instructions]
00:27 I would now like to turn the conference over to Ms. Juli Miller. Please go ahead ma’am.
Juli Miller
00:33 Good morning, and welcome to Adaptimmune's conference call to discuss our full-year and fourth quarter 2021 financial results and business updates. I would ask you to please review the full text of our forward-looking statements from this morning's press release. We anticipate making projections during this call, and actual results could differ materially due to several factors, including those outlined in our filings with the SEC.
00:59 Adrian Rawcliffe, our Chief Executive Officer, is with me for the prepared portion of this call. Other members of our management team will be available for Q&A.
01:09 With that, I'll turn the call over to Adrian Rawcliffe. Ad?
- Read more current ADAP analysis and news
- View all earnings call transcripts